| 02:38p | SHIFA HOSPXD : Transaction of 200 shares of Shifa International Hospitals Limited | AQ |
| 02:38p | SHIFA HOSPXD : Transaction of 10,000 shares of Shifa International Hospitals Limited | AQ |
| 02:00p | ATARA BIOTHERAPEUTICS : Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma (EBV+ LMS) | AQ |
| 01:35p | PFIZER : Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV | AQ |
| 01:32p | IDERA PHARMACEUTICALS : Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment | AQ |
| 01:28p | CHEMESIS INTERNATIONAL INC : . Announces Second Tranche of Convertible Debenture Offering | AQ |
| 01:26p | JOHNSON & JOHNSON : Senator Markey Queries FDA on Asbestos and Baby Powder Products | AQ |
| 01:25p | AGP : Pakistan Stock Exchange Limited Closing Rate of PHARMACEUTICALS Dated 14-12-2018 - Press Release issued by Pakistan Stock Exchange Limited | AQ |
| 01:13p | JOHNSON & JOHNSON : Statement on Reuters Talc Article | AQ |
| 01:12p | JOHNSON & JOHNSON : Janssen Submits Supplemental New Drug Application to FDA for XARELTO (Rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients | AQ |
| 12:32p | ALMIRALL : And X-Chem Announce Dermatology-Focused Drug Discovery Collaboration | AQ |
| 12:30p | JOHNSON AND JOHNSON PRODUCING DELIBERATELY 'CANCER' CAUSING BABY POWDER FOR YEARS : Report | AQ |
| 12:09p | BELLICUM PHARMACEUTICALS : Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO | AQ |
| 12:08p | CYNATA THERAPEUTICS : Gets Major Funding From NHMRC For Second Phase Clinical Trial In Osteoarthritis | AQ |
| 12:08p | MAX INDIA : KKR-led Radiant in talks to acquire Max Healthcare | AQ |
| 12:08p | LEAP THERAPEUTICS : Presents TRX518 Data at ESMO Immuno-Oncology Congress 2018 and Updated Data from DKN-01 Study in Biliary Tract Cancer | AQ |
| 12:07p | JOHNSON & JOHNSON : Wall Street plummets amidst world recession fears | AQ |
| 12:04p | ORCHARD THERAPEUTICS : and SIRION Biotech Announce Licensing Agreement to Enhance Gene Therapy Manufacturing Efficiency | AQ |
| 12:04p | JOHNSON & JOHNSON : Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients | AQ |
| 12:04p | ORCHARD THERAPEUTICS : and SIRION Biotech Announce Licensing Agreement to Enhance Gene Therapy Manufacturing Efficiency | AQ |
| 12:04p | SANOFI : starts remaining phase 3 clinical trials of Hanmis diabetes drug candidate | AQ |
| 12:04p | EXTENDICARE : Announces December 2018 Dividend of C$0.04 per Share | AQ |
| 12:03p | CANNABIX TECHNOLOGIES : Cannabis Users Drive High, and Crashes Are on the Rise-- CFN Media | AQ |
| 12:03p | SIENNA SENIOR LIVING : Announces December Dividend | AQ |
| 12:03p | SENSORION : Announces Positive Topline Results From Seliforant Phase 2a Study | AQ |
| 12:02p | AURORA CANNABIS : investing $10M in marijuana retailer High Tide | AQ |
| 12:00p | NEUROCRINE BIOSCIENCES : slumps as Tourettes drug fails clinical trial | AQ |
| 12:00p | SUPERNUS PHARMACEUTICALS : Announces FDA Approval of sNDA to Expand Oxtellar XR Label to Include Monotherapy | AQ |
| 11:59a | LUYE PHARMA : submits its Parkinsons drug for clinical trial approval | AQ |
| 11:58a | SECOND SIGHT MEDICAL PRODUCTS : Completes $3 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors | AQ |
| 11:58a | FLOWR : Hires Lance Emanuel as President | AQ |
| 11:12a | BERGENBIO : announces a change to its Board of Directors | AQ |
| 10:18a | SONOMA PHARMACEUTICALS : Announces Management Changes | AQ |
| 10:18a | ALDER BIOPHARMACEUTICALS : Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | AQ |
| 10:17a | PARADIGM BIOPHARMACEUTICALS : has results pending for phase 2b clinical trial | AQ |
| 10:16a | FRESENIUS MEDICAL CARE : acquires additional renal hospitals and dialysis centers in China | AQ |
| 10:16a | KALVISTA PHARMACEUTICALS : Reports Fiscal Second Quarter Results | AQ |
| 09:16a | CURALEAF : Md. medical pot regulators plan hearing on rules many fear threaten competition | AQ |
| 09:01a | ROCHE : Genentech Develop Antibiotic Effective Against Gram-Negative Bacteria, with Potential to Lead to New Class of Antibiotics | AQ |
| 08:31a | BeiGene Announces Updated Phase 1A/1B Data on Tislelizumab Presented at the European Society for Medical Oncology Immuno-Oncology Congress | GL |
| 07:42a | JOHNSON & JOHNSON : Stocks plunge to 8-month lows | AQ |
| 06:50a | EPIZYME : Family of Lakewood toddler with brain tumor desperate for unapproved drug | AQ |
| 04:51a | HENRY SCHEIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL : Kahn Swick & Foti, LLC Investigates the Officers and Directors of Henry Schein, Inc. - HSIC | BU |
| 02:10a | Medicenna Announces Pricing of Marketed Offering of Units | NE |
| 01:22a | JOHNSON & JOHNSON : Global growth worries, J&J's tumble drag Wall St lower | AQ |
| 12:39a | GLANCY PRONGAY & MURRAY LLP : Announces Extended Class Period in Securities Class Action on Behalf of Align Technology, Inc. Investors | BU |
| 12:32a | TEVA PHARMACEUTICAL INDUSTRIES : Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications | BU |
| 12:25a | Abattis Bioceuticals Corp., A Fully Integrated Medical Marijuana Company, CEO Clip Video | NE |
| 12:25a | ABATTIS BIOCEUTICALS CORP. : A Fully Integrated Medical Marijuana Company, CEO Clip Video | AQ |
| 12/14 | MEDICARE : Israeli soldiers injure Palestinian by live shots near Hebron | AQ |
United Kingdom
France
Deutschland
Schweiz (DE)
